Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Capital Expenditures (2010 - 2022)

Nephros' quarterly Capital Expenditures came in at $103000.0 in Q2 2022, up 202.94% quarter-over-quarter from $34000.0 in Q1 2022.

Nephros has reported Capital Expenditures for 6 years, with the latest figure at $103000.0 in Q2 2022.

  • For the quarter ending Q2 2022, Capital Expenditures changed N/A year-over-year to $103000.0; the trailing twelve-month figure through Sep 2024 stood at $103000.0 (changed N/A YoY), and the FY2024 full-year result was $55000.0, down 26.67% from the prior year.
  • Capital Expenditures for Q2 2022 stood at $103000.0, up from $34000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $103000.0 in Q2 2022, with the low at $13000.0 in Q3 2020.
  • Average Capital Expenditures over 3 years is $37200.0, with a median of $23000.0 recorded in 2021.
  • Year-over-year, Capital Expenditures changed 0.0% in 2021 and jumped 47.83% in 2022.
  • Tracing NEPH's Capital Expenditures over 3 years: stood at $13000.0 in 2020, then changed by 0.0% to $13000.0 in 2021, then jumped by 692.31% to $103000.0 in 2022.
  • The last three Capital Expenditures figures came in at $103000.0 (Q2 2022), $34000.0 (Q1 2022), and $13000.0 (Q3 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 103.30 Mn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 125.00 Mn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 33.65 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 26.10 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 84.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 102.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 30.79 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 137.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 65.40 Mn
10 Nephros 38.93 Mn 34.91 Mn 2.99 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 103,000.00
Jun 30, 2022 103,000.00
Mar 31, 2022 34,000.00
Mar 31, 2022 34,000.00
Sep 30, 2021 13,000.00
Sep 30, 2021 13,000.00
Mar 31, 2021 23,000.00
Mar 31, 2021 23,000.00
Sep 30, 2020 13,000.00
Sep 30, 2020 13,000.00
Sep 30, 2016 5,000.00
Sep 30, 2016 5,000.00
Jun 30, 2016 14,000.00
Jun 30, 2016 14,000.00
Mar 31, 2016 26,000.00
Mar 31, 2016 26,000.00
Dec 31, 2012 1,000.00
Dec 31, 2012 1,000.00
Dec 31, 2010 24,000.00
Dec 31, 2010 24,000.00